Copy to clipboard 
Zimmer Biomet appointed Ivan Tornos as President and Chief Executive Officer, effective immediately. Mr. Tornos has most recently served as Chief Operating Officer of Zimmer Biomet, a role he has held since early 2021. He takes over as President and CEO from Bryan Hanson, who has served as President and CEO since late 2017. Mr. Hanson is departing to take on another CEO role at 3 M’s healthcare division.
Suketu Upadhyay, who joined Zimmer Biomet in 2019 as Executive Vice President and Chief Financial Officer, is expanding his role to also include full responsibility for overseeing global Operations and Supply Chain functions.
The company is reaffirming its full-year 2023 financial guidance as outlined in its second quarter financial results.
“It is an honor to be appointed CEO of Zimmer Biomet at a time when our execution is extremely strong and our innovation momentum is at an all-time high,” said Mr. Tornos. “I am grateful for Bryan’s leadership in transforming the Company and am now looking forward to leading the team and accelerating our ZB strategy to drive continued growth and boldly advance the standard of musculoskeletal care.”
Mr. Tornos joined Zimmer Biomet in 2018 as Group President, Orthopedics, and a year later was named Group President, Global Businesses and the Americas. He was appointed Chief Operating Officer in 2021 with responsibility for overseeing all global businesses at Zimmer Biomet, as well as leading the global operations, clinical and medical education and global R&D and New Product Development functions. In this role, he had oversight of the Americas and the Europe, Middle East and Africa (EMEA) regions.
Prior to joining Zimmer Biomet, Mr. Tornos held leadership roles at Becton Dickinson, C.R. Bard, Covidien International, Baxter International and Johnson & Johnson.
Mr. Hanson will be assuming the role of CEO of the healthcare spinoff of 3M. During his tenure at Zimmer Biomet, he spearheaded the company’s transformation including the spinoff of the Spine and Dental franchises to an independent company, ZimVie.
During the transformation, Mr. Hanson guided the company’s strategy toward higher growth segments like sports medicine, extremities and enabling technology. The company rapidly expanded its ZBEdge digital ecosystem, and the launch of its ROSA knee and hip robot continues to drive competitive growth for the Zimmer Biomet. Mr. Hanson leaves the company within reach of its mid-single-digit growth targets and armed with a revitalized portfolio,
“The last five and a half years at the helm of Zimmer Biomet have been transformational, not just for the Company, but for me, as well,” said Mr. Hanson. “I have the utmost confidence in Ivan, the entire ZB team and the strength of the business. I cannot think of a better leader to continue to move the ZB mission forward and deliver value for patients, customers and shareholders.”
Source: Zimmer Biomet
Zimmer Biomet appointed Ivan Tornos as President and Chief Executive Officer, effective immediately. Mr. Tornos has most recently served as Chief Operating Officer of Zimmer Biomet, a role he has held since early 2021. He takes over as President and CEO from Bryan Hanson, who has served as President and CEO since late 2017. Mr. Hanson is...
Zimmer Biomet appointed Ivan Tornos as President and Chief Executive Officer, effective immediately. Mr. Tornos has most recently served as Chief Operating Officer of Zimmer Biomet, a role he has held since early 2021. He takes over as President and CEO from Bryan Hanson, who has served as President and CEO since late 2017. Mr. Hanson is departing to take on another CEO role at 3 M’s healthcare division.
Suketu Upadhyay, who joined Zimmer Biomet in 2019 as Executive Vice President and Chief Financial Officer, is expanding his role to also include full responsibility for overseeing global Operations and Supply Chain functions.
The company is reaffirming its full-year 2023 financial guidance as outlined in its second quarter financial results.
“It is an honor to be appointed CEO of Zimmer Biomet at a time when our execution is extremely strong and our innovation momentum is at an all-time high,” said Mr. Tornos. “I am grateful for Bryan’s leadership in transforming the Company and am now looking forward to leading the team and accelerating our ZB strategy to drive continued growth and boldly advance the standard of musculoskeletal care.”
Mr. Tornos joined Zimmer Biomet in 2018 as Group President, Orthopedics, and a year later was named Group President, Global Businesses and the Americas. He was appointed Chief Operating Officer in 2021 with responsibility for overseeing all global businesses at Zimmer Biomet, as well as leading the global operations, clinical and medical education and global R&D and New Product Development functions. In this role, he had oversight of the Americas and the Europe, Middle East and Africa (EMEA) regions.
Prior to joining Zimmer Biomet, Mr. Tornos held leadership roles at Becton Dickinson, C.R. Bard, Covidien International, Baxter International and Johnson & Johnson.
Mr. Hanson will be assuming the role of CEO of the healthcare spinoff of 3M. During his tenure at Zimmer Biomet, he spearheaded the company’s transformation including the spinoff of the Spine and Dental franchises to an independent company, ZimVie.
During the transformation, Mr. Hanson guided the company’s strategy toward higher growth segments like sports medicine, extremities and enabling technology. The company rapidly expanded its ZBEdge digital ecosystem, and the launch of its ROSA knee and hip robot continues to drive competitive growth for the Zimmer Biomet. Mr. Hanson leaves the company within reach of its mid-single-digit growth targets and armed with a revitalized portfolio,
“The last five and a half years at the helm of Zimmer Biomet have been transformational, not just for the Company, but for me, as well,” said Mr. Hanson. “I have the utmost confidence in Ivan, the entire ZB team and the strength of the business. I cannot think of a better leader to continue to move the ZB mission forward and deliver value for patients, customers and shareholders.”
Source: Zimmer Biomet
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
